Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.48 |
| ▸ | DRD3 | P35462 | 9/20 | 0.43 |
| ▸ | HTR1A | P08908 | 7/20 | 0.42 |
| ▸ | DRD1 | P21728 | 7/20 | 0.42 |
| ▸ | DRD4 | P21917 | 7/20 | 0.42 |
| ▸ | DRD5 | P21918 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309521 | 0.82 | QDPR (0.51) | DRD2 | |
| SCHEMBL23931791 | 0.79 | CA12 (0.52) | — | |
| SCHEMBL8242625 | 0.79 | KDM4E (0.39) | DRD2DRD3HTR1ADRD1DRD4 | |
| SCHEMBL1821857 | 0.79 | DRD2 (0.52) | DRD2DRD4KDM4ESLC18A3 | |
| Seridopidine SCHEMBL1008691 | 0.78 | DRD2 (0.53) | DRD2DRD3KDM4E | |
| Seridopidine SCHEMBL29941400 | 0.78 | DRD2 (0.53) | DRD2DRD3KDM4E | |
| Seridopidine SCHEMBL1010113 | 0.77 | DRD2 (0.52) | DRD2DRD3KDM4E | |
| SCHEMBL4819670 | 0.76 | DRD2 (0.78) | DRD2DRD3HTR1ADRD1DRD4 | |
| SCHEMBL27744632 | 0.76 | KDM4E (0.36) | DRD2DRD3DRD4KDM4E | |
| SCHEMBL27684546 | 0.75 | KDM4E (0.40) | DRD2KDM4ESLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | DRD2 1/4885DRD3 4/4885HTR1A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.